TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease
Brief Summary: The JIKEI HEART Study has been designed to investigate whether concomitant treatment with valsartan, an angiotensin II receptor blocker (ARB), in addition to conventional treatment, will improve the prognosis of 3000 Japanese patients with cardiovascular diseases.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Tablets | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Tablets; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
D: Arm Label: Aggrenox, Clopidogrel placebo, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis | Arm Label: Aggrenox placebo, clopidogrel,, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Micardis, Drug: Aggrenox placebo, Drug: Clopidogrel | Arm Label: Aggrenox, clop placebo, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis placebo | Arm Label: Aggrenox plcebo, clop, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox placebo, Drug: Clopidogrel, Drug: Micardis placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PPAR Alpha (LY518674): A Phase 2 Study of the Combinatorial Effect of LY518674 and Atorvastatin in Subjects With Hypercholesterolemia
Brief Summary: The purposes of this study are to determine:

* The safety of the study medication and any side effects that might be associated with it
* Whether the study medication can help patients with high levels of "bad" cholesterol (low-density lipoprotein-cholesterol \[LDL-C\]), alone or in combination with additional study medication


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Intervention Type: DRUG; Name: REGN727; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4
B: Intervention Type: DRUG; Name: PPAR alpha; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Aspirin + Atorvastatin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Aspirin + Atorvastatin; Assigned to Arm(s): 4
D: Arm Label: active treatment; Type: EXPERIMENTAL; Interventions: Drug: atorvastatin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): active treatment | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Impact and Intervention for Diarrhea in Brazil
Brief Summary: The primary objectives of this study are to determine the effect of 1 year supplementation of Vitamin A, Zinc, and Vitamin A plus Zinc compared to placebo on the Height for Age Z Score (HAZ) and the number of episodes of diarrhea and number of days of diarrhea at one year in children living in a Brazilian slum. Study participants will include 280 children ages 2 months to 8 years old, with a Height for Age Z score (HAZ) less than median for the Parque Universitario community, living in Brazilian favela. There is also a sub study to determine if ten days of glutamine delivered as an oral bolus improves the health of the digestive system.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
C: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Glutamine | Arm Label: b; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: c; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: d; Type: PLACEBO_COMPARATOR; Interventions: Drug: glycine | Arm Label: e; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: f; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A, Drug: zinc | Intervention Type: DRUG; Name: Glutamine; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): b, c, e, f | Intervention Type: DRUG; Name: glycine; Assigned to Arm(s): d | Intervention Type: DRUG; Name: zinc; Assigned to Arm(s): b, c, e, f
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: vitamin A supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin A supplements | Intervention Type: DRUG; Name: vitamin A supplements; Assigned to Arm(s): vitamin A supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Impact and Intervention for Diarrhea in Brazil
Brief Summary: The primary objectives of this study are to determine the effect of 1 year supplementation of Vitamin A, Zinc, and Vitamin A plus Zinc compared to placebo on the Height for Age Z Score (HAZ) and the number of episodes of diarrhea and number of days of diarrhea at one year in children living in a Brazilian slum. Study participants will include 280 children ages 2 months to 8 years old, with a Height for Age Z score (HAZ) less than median for the Parque Universitario community, living in Brazilian favela. There is also a sub study to determine if ten days of glutamine delivered as an oral bolus improves the health of the digestive system.


Options:
A: Arm Label: Vitamin B12; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin B12 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12; Assigned to Arm(s): Vitamin B12 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Zinc | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamins and minerals other than zinc | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamins plus zinc and other minerals | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamins and minerals other than zinc; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamins plus zinc and other minerals; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 4
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: zinc | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: iron + copper | Intervention Type: DIETARY_SUPPLEMENT; Name: zinc; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: iron + copper; Assigned to Arm(s): 2
D: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Glutamine | Arm Label: b; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: c; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: d; Type: PLACEBO_COMPARATOR; Interventions: Drug: glycine | Arm Label: e; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: f; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A, Drug: zinc | Intervention Type: DRUG; Name: Glutamine; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): b, c, e, f | Intervention Type: DRUG; Name: glycine; Assigned to Arm(s): d | Intervention Type: DRUG; Name: zinc; Assigned to Arm(s): b, c, e, f

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Impact and Intervention for Diarrhea in Brazil
Brief Summary: The primary objectives of this study are to determine the effect of 1 year supplementation of Vitamin A, Zinc, and Vitamin A plus Zinc compared to placebo on the Height for Age Z Score (HAZ) and the number of episodes of diarrhea and number of days of diarrhea at one year in children living in a Brazilian slum. Study participants will include 280 children ages 2 months to 8 years old, with a Height for Age Z score (HAZ) less than median for the Parque Universitario community, living in Brazilian favela. There is also a sub study to determine if ten days of glutamine delivered as an oral bolus improves the health of the digestive system.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Arm Label: Vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU); Assigned to Arm(s): Placebo, Vitamin A
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: vitamin A supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin A supplements | Intervention Type: DRUG; Name: vitamin A supplements; Assigned to Arm(s): vitamin A supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Glutamine | Arm Label: b; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: c; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: d; Type: PLACEBO_COMPARATOR; Interventions: Drug: glycine | Arm Label: e; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: f; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A, Drug: zinc | Intervention Type: DRUG; Name: Glutamine; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): b, c, e, f | Intervention Type: DRUG; Name: glycine; Assigned to Arm(s): d | Intervention Type: DRUG; Name: zinc; Assigned to Arm(s): b, c, e, f
D: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: retinyl palmitate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: retinyl palmitate; Assigned to Arm(s): Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Rehabilitation After Hip Fracture: A Randomized Controlled Trial Comparing Different Vitamin D and Rehabilitation Programs
Brief Summary: The aim of this study is to compare a low versus high intensity physiotherapy early rehabilitation program combined with a low versus high dose vitamin D early rehabilitation program in a randomized controlled trial among elderly patients with acute hip fracture in an acute care setting. The primary outcome to be compared between treatment arms is the rate of falls during a 12-month follow-up. Secondary outcomes are injurious falls, number of persons who fell, low-trauma fractures (at the hip, forearm, humerus, pelvis, ankle, spine, femur, tibia), disability, quality of life (Euro-Qol), mortality and health care utilization. Another secondary outcome will be admission to nursing home compared between treatment arms among subjects, who are community-dwelling prior to the index hip fracture. Admission to nursing home is the marker of loss of independence for the individual, but also triggers high cost for the society.

The study will provide new early rehabilitation guidelines to allocate health care resources efficiently in the acute care setting. Eventually and most importantly, the study will help improve outcomes in patients with hip fractures.


Options:
A: Arm Label: Functional training group; Type: EXPERIMENTAL; Interventions: Other: Functional training program | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Functional training program; Assigned to Arm(s): Functional training group
B: Intervention Type: DRUG; Name: MK0677; Assigned to Arm(s): N/A
C: Arm Label: physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: physiotherapy | Arm Label: conventional treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: physiotherapy; Assigned to Arm(s): physiotherapy
D: Intervention Type: DRUG; Name: cholecalciferol; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Physiotherapy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Rehabilitation After Hip Fracture: A Randomized Controlled Trial Comparing Different Vitamin D and Rehabilitation Programs
Brief Summary: The aim of this study is to compare a low versus high intensity physiotherapy early rehabilitation program combined with a low versus high dose vitamin D early rehabilitation program in a randomized controlled trial among elderly patients with acute hip fracture in an acute care setting. The primary outcome to be compared between treatment arms is the rate of falls during a 12-month follow-up. Secondary outcomes are injurious falls, number of persons who fell, low-trauma fractures (at the hip, forearm, humerus, pelvis, ankle, spine, femur, tibia), disability, quality of life (Euro-Qol), mortality and health care utilization. Another secondary outcome will be admission to nursing home compared between treatment arms among subjects, who are community-dwelling prior to the index hip fracture. Admission to nursing home is the marker of loss of independence for the individual, but also triggers high cost for the society.

The study will provide new early rehabilitation guidelines to allocate health care resources efficiently in the acute care setting. Eventually and most importantly, the study will help improve outcomes in patients with hip fractures.


Options:
A: Intervention Type: DRUG; Name: cholecalciferol; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Physiotherapy; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): N/A
C: Arm Label: Lite OJ with Ca and VitD; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Reduced energy (lite) OJ fortified with Calcium and Vitamin D, Behavioral: Nutrition Counseling | Arm Label: Lite OJ without Ca and VitD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nutrition Counseling, Dietary Supplement: Reduced energy (lite) OJ without Calcium and Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Reduced energy (lite) OJ fortified with Calcium and Vitamin D; Assigned to Arm(s): Lite OJ with Ca and VitD | Intervention Type: BEHAVIORAL; Name: Nutrition Counseling; Assigned to Arm(s): Lite OJ with Ca and VitD, Lite OJ without Ca and VitD | Intervention Type: DIETARY_SUPPLEMENT; Name: Reduced energy (lite) OJ without Calcium and Vitamin D; Assigned to Arm(s): Lite OJ without Ca and VitD
D: Intervention Type: DRUG; Name: Caltrate® 600 + D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Weight loss intervention; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Asthma Communication in Minority Families
Brief Summary: The purpose of this study is to determine if teaching children with asthma how to talk to their doctor about controlling their asthma including symptom frequency in an asthma diary and medication use techniques, will result in less symptom and missed school days, fewer emergency room visits and reduce the cost of asthma health care.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Asthma Communication Education | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Asthma Education | Intervention Type: BEHAVIORAL; Name: Asthma Communication Education; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Standard Asthma Education; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Disease Management; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Disease Management + Educational Home Visits; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Using Parent Mentors to Improve Asthma Care for Urban Minority Children; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Home-based adherence monitoring; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: INternational VErapamil SR Trandolapril STudy
Brief Summary: Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release \[SR\] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA).


Options:
A: Arm Label: Aggressive BP lowering; Type: EXPERIMENTAL; Interventions: Procedure: Aggressive BP lowering | Arm Label: Modest BP lowering; Type: ACTIVE_COMPARATOR; Interventions: Procedure: modest blood pressure lowering | Intervention Type: PROCEDURE; Name: Aggressive BP lowering; Assigned to Arm(s): Aggressive BP lowering | Intervention Type: PROCEDURE; Name: modest blood pressure lowering; Assigned to Arm(s): Modest BP lowering
B: Intervention Type: DRUG; Name: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atenolol/HCTZ/Trandolapril; Assigned to Arm(s): N/A
C: Arm Label: Intensive Control of SBP; Type: EXPERIMENTAL; Interventions: Drug: Intensive control of SBP | Arm Label: Standard Control of SBP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of SBP | Intervention Type: DRUG; Name: Intensive control of SBP; Assigned to Arm(s): Intensive Control of SBP | Intervention Type: DRUG; Name: Standard control of SBP; Assigned to Arm(s): Standard Control of SBP
D: Arm Label: Intensive; Type: EXPERIMENTAL; Interventions: Other: Anti-hypertensive therapy to SBP 130 mm Hg | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Anti-hypertensive therapy to SBP 145 mm Hg | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 130 mm Hg; Assigned to Arm(s): Intensive | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 145 mm Hg; Assigned to Arm(s): Standard

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: INternational VErapamil SR Trandolapril STudy
Brief Summary: Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release \[SR\] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA).


Options:
A: Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP control | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Intervention Type: DRUG; Name: Intensive BP control; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control
B: Intervention Type: DRUG; Name: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atenolol/HCTZ/Trandolapril; Assigned to Arm(s): N/A
C: Arm Label: intensive blood pressure control; Type: ACTIVE_COMPARATOR; Interventions: Drug: control systolic blood pressure less than 120 mmHg | Arm Label: standard blood pressure control; Type: ACTIVE_COMPARATOR; Interventions: Drug: control systolic blood pressure less than 140 mmHg | Intervention Type: DRUG; Name: control systolic blood pressure less than 120 mmHg; Assigned to Arm(s): intensive blood pressure control | Intervention Type: DRUG; Name: control systolic blood pressure less than 140 mmHg; Assigned to Arm(s): standard blood pressure control
D: Arm Label: Intensive Control of SBP; Type: EXPERIMENTAL; Interventions: Drug: Intensive control of SBP | Arm Label: Standard Control of SBP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of SBP | Intervention Type: DRUG; Name: Intensive control of SBP; Assigned to Arm(s): Intensive Control of SBP | Intervention Type: DRUG; Name: Standard control of SBP; Assigned to Arm(s): Standard Control of SBP

Answer: B